Junshi Biosciences (01877): The supplementary application for the use of tislelizumab combined with chemotherapy in the neoadjuvant treatment of resectable stage II-III non-small cell lung cancer patients has been accepted.

Intelligence Finance News, GenScript Biotech (01877) announced that the company recently received a "Notice of Acceptance" issued by the National Medical Products Administration. The supplemental application for indication revision of Teripulimab Monoantibody (trade name: Tuyi, product code: JS001) for neoadjuvant therapy in combination with platinum-containing chemotherapy, followed by monotherapy as adjuvant therapy, for adult patients with resectable stage II-III non-small cell lung cancer (NSCLC) has been accepted. The indication for this application has been expanded from adult patients with resectable stage IIIA-IIIB non-small cell lung cancer to adult patients with resectable stage II-III non-small cell lung cancer.